Neopterin as an inflammatory prognostic biomarker in male With systemic disease

Background :The serum level of neopterin, a marker associated with cell-mediated immunity, is increased in coronary artery disease and chronic kidney disease (CKD) especially in end stage renal disease (ESRD ) and may be a risk marker for adverse outcomes resulting from these diseases. Objective: to compare the levels of neopterin in two systemic inflammatory diseases cardiovascular disease and end stage disease(CVD& ESRD) and study its correlationwith other serum parameters. Subjects & Methods: The study involved 38 male patients with ESRD and 40 male patients with CVD (age range of 30- 60 years ) .They were attending Kidney disease and Transplantation Unit and Coronary Care Unit (CCU) at Baghdad Teaching Hospital ( Medical City ) during the period from December 2012 to March 2013 with 58 healthy subjects (control group ) of matching age and weight. Fasting venous blood was obtained for glucose, lipid profile, urea and creatinine measurement which were done immediately after separation of the serum by standard routine methods. The determination of neopterin was done using Enzyme-Linked Immuno Sorbent Assay. (ELISA, Sandwich assay). Results:the results revealed a significant difference in neopterin level between each group of patients (CVD & ESRD) with its control group (45.5 ± 11.9.vs16.48± 3.09) and (95.89 ± 11.3 vs.16.66± 2.83) respectively. In addition to inverse correlation between neopterin and estimated glomerular filtration rate (eGFR) in ESRD patients (p< 0.05), and significant inverse correlation with triglyceride (TG) in CVD patients (p < 0.05). Conclusion: The most important results of this study suggest that the neopterin level, which is considered a useful marker of systemic inflammation, in ESRD patients is higher than in CVD patients. Date Submitted: Date Accepted: Address for Correspondence: